Vaccinex, Inc. VCNX
We take great care to ensure that the data presented and summarized in this overview for VACCINEX, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VCNX
Top Purchases
Top Sells
About VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Insider Transactions at VCNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2024
|
Maurice Zauderer President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
46,153
+13.41%
|
$138,459
$3.25 P/Share
|
|
Nov 14
2024
|
Albert Friedberg Director |
BUY
Grant, award, or other acquisition
|
Indirect |
30,756
+2.84%
|
$92,268
$3.25 P/Share
|
|
Sep 18
2024
|
Albert Friedberg Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
240,009
+10.09%
|
$1,200,045
$5.64 P/Share
|
|
Sep 18
2024
|
Maurice Zauderer President and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
113,650
+11.8%
|
$568,250
$5.64 P/Share
|
|
Aug 09
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
100
+0.01%
|
$400
$4.51 P/Share
|
|
Aug 06
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
2,753
+0.35%
|
$11,012
$4.92 P/Share
|
|
Aug 05
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
3,653
+0.47%
|
$14,612
$4.6 P/Share
|
|
Aug 01
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
11,703
+1.49%
|
$46,812
$4.72 P/Share
|
|
Jul 31
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+8.43%
|
$1,200,000
$6.52 P/Share
|
|
May 30
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
861
+0.15%
|
$4,305
$5.2 P/Share
|
|
May 29
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
957
+0.17%
|
$3,828
$4.95 P/Share
|
|
May 10
2024
|
Van Strydonck, Gerald E. Director |
BUY
Grant, award, or other acquisition
|
Direct |
543
+50.0%
|
$2,715
$5.75 P/Share
|
|
Apr 19
2024
|
Albert Friedberg Director |
BUY
Open market or private purchase
|
Indirect |
282
+0.05%
|
$1,128
$4.73 P/Share
|
|
Mar 28
2024
|
Albert Friedberg Director |
BUY
Grant, award, or other acquisition
|
Indirect |
102,960
+15.52%
|
$720,720
$7.77 P/Share
|
|
Mar 28
2024
|
Maurice Zauderer President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
38,610
+21.84%
|
$270,270
$7.77 P/Share
|
|
Feb 08
2024
|
Albert Friedberg Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,655,172
+20.54%
|
$0
$0.72 P/Share
|
|
Feb 08
2024
|
Maurice Zauderer President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
413,793
+22.9%
|
$0
$0.72 P/Share
|
|
Dec 26
2023
|
Van Strydonck, Gerald E. Director |
SELL
Open market or private sale
|
Direct |
3,149
-100.0%
|
$0
$0.72 P/Share
|
|
Dec 08
2023
|
Van Strydonck, Gerald E. Director |
SELL
Open market or private sale
|
Direct |
1,334
-29.76%
|
$0
$0.67 P/Share
|
|
Oct 04
2023
|
Maurice Zauderer President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+18.44%
|
$0
$0.97 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.29M shares |
|---|---|
| Exercise of conversion of derivative security | 354K shares |
| Open market or private purchase | 220K shares |
| Open market or private sale | 4.48K shares |
|---|